



## ADDENDUM

# Addendum: Pharmacogenetic testing of *CYP2C9* and *VKORC1* alleles for warfarin



Ting Wen, C. Anwar A. Chahal, Melanie A. Manning; on behalf of the ACMG Professional Practice and Guidelines Committee

Addendum to: “Pharmacogenetic testing of *CYP2C9* and *VKORC1* alleles for warfarin.” David A. Flockhart, MD, PhD, Dennis O’Kane, PhD, Marc S. Williams, MD, Michael S. Watson, PhD; ACMG Working Group on Pharmacogenetic Testing of *CYP2C9*, *VKORC1* Alleles for Warfarin Use. *Genetics in Medicine* 10(2):139-150 (2008). <https://doi.org/10.1097/GIM.0b013e318163c35f>, published online 01 February 2008.

### ARTICLE INFO

This document was retired by the ACMG Board of Directors as of 18 September 2023 with the following addendum.

#### Article history:

Received 25 September 2023

Accepted 26 September 2023

At their meeting on August 9, 2023, the Professional Practice and Guidelines Committee members voted to retire the Policy Statement, “Pharmacogenetic testing of *CYP2C9* and *VKORC1* alleles for warfarin,” which was originally published in 2008. The Professional Practice and Guidelines Committee members concluded that this document is outdated and is expected to be superseded by a newly drafted comprehensive practice guideline. Although portions of the original document were believed to hold continuing relevance for clinical testing laboratories, it was the belief of the Professional Practice and Guidelines Committee members that, with the advent of sequencing techniques, the availability of several key statements from relevant agencies, the need for updates on clinical trials, and the extended understanding about *CYP2C9* haplotypes,<sup>1-4</sup> the new practice guideline would be expected to address these unmet knowledge gaps.

### Conflict of Interest

The authors declare no conflicts of interest.

### References

1. Johnson JA, Caudle KE, Gong L, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for pharmacogenetics-guided warfarin dosing: 2017 update. *Clin Pharmacol Ther.* 2017;102(3):397-404. <http://doi.org/10.1002/cpt.668>
2. Pratt VM, Cavallari LH, Del Tredici AL, et al. Recommendations for clinical *CYP2C9* genotyping allele selection: a joint recommendation of the Association for Molecular Pathology and College of American Pathologists. *J Mol Diagn.* 2019;21(5):746-755. <http://doi.org/10.1016/j.jmoldx.2019.04.003>
3. Dean L. Warfarin therapy and *VKORC1* and *CYP* genotype. In: Pratt VM, Scott SA, Pirmohamed M, et al., eds. Updated June 11, 2018. *Medical Genetics Summaries*. National Center for Biotechnology Information; 2012.
4. Van der Lee M, Rowell WJ, Menafrá R, Guchelaar HJ, Swen JJ, Anwar SY. Application of long-read sequencing to elucidate complex pharmacogenomic regions: a proof of principle. *Pharmacogenomics J.* 2022;22(1):75-81. <http://doi.org/10.1038/s41397-021-00259-z>

Email address: ACMG ([documents@acmg.net](mailto:documents@acmg.net))

doi: <https://doi.org/10.1016/j.gim.2023.100990>

1098-3600/© 2023 Published by Elsevier Inc. on behalf of American College of Medical Genetics and Genomics.